MUC1 Drives the Progression and Chemoresistance of Clear Cell Renal Carcinomas - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2024

MUC1 Drives the Progression and Chemoresistance of Clear Cell Renal Carcinomas

Résumé

While the transmembrane glycoprotein mucin 1 (MUC1) is clustered at the apical borders of normal epithelial cells, with transformation and loss of polarity, MUC1 is found at high levels in the cytosol and is uniformly distributed over the entire surface of carcinoma cells, where it can promote tumor progression and adversely affects the response to therapy. Clear cell renal cell carcinoma (ccRCC), the main histotype of kidney cancer, is typically highly resistant to conventional and targeted therapies for reasons that remain largely unknown. In this context, we investigated whether MUC1 also plays a pivotal role in the cellular and molecular events driving ccRCC progression and chemoresistance. We showed, using loss- and gain-of-function approaches in ccRCC-derived cell lines, that MUC1 not only influences tumor progression but also induces a multi-drug-resistant profile reminiscent of the activation of ABC drug efflux transporters. Overall, our results suggest that targeting MUC1 may represent a novel therapeutic approach to limit ccRCC progression and improve drug sensitivity.
Fichier principal
Vignette du fichier
cancers-16-00391.pdf (2.07 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

inserm-04479812 , version 1 (27-02-2024)

Licence

Paternité

Identifiants

Citer

Emma Bourdon, Thomas Swierczewski, Marine Goujon, Nihad Boukrout, Sandy Fellah, et al.. MUC1 Drives the Progression and Chemoresistance of Clear Cell Renal Carcinomas. Cancers, 2024, 16 (2), pp.391. ⟨10.3390/cancers16020391⟩. ⟨inserm-04479812⟩
12 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More